Switch theme
Sign up to access all valuation multiples
OrthoPediatrics Corp is a medical device company. The company is engaged in providing products to the pediatric orthopedic market. The firm designs develop and commercialize implants and instruments to meet the needs of surgeons and patients. Its products, include PediLoc, PediPlates, Cannulated Screws, PediFlexTM nail, PediNailTM, PediLoc Tibia and ACL Reconstruction System among others.
2007
562
LTM Revenue $219M
LTM EBITDA $11.5M
$509M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OrthoPediatrics has a last 12-month revenue (LTM) of $219M and a last 12-month EBITDA of $11.5M.
In the most recent fiscal year, OrthoPediatrics achieved revenue of $205M and an EBITDA of -$10.4M.
OrthoPediatrics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OrthoPediatrics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $219M | XXX | $205M | XXX | XXX | XXX |
| Gross Profit | $159M | XXX | $149M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $11.5M | XXX | -$10.4M | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | -5% | XXX | XXX | XXX |
| EBIT | -$32.5M | XXX | -$29.5M | XXX | XXX | XXX |
| EBIT Margin | -15% | XXX | -14% | XXX | XXX | XXX |
| Net Profit | -$34.9M | XXX | -$37.8M | XXX | XXX | XXX |
| Net Margin | -16% | XXX | -18% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $29.3M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, OrthoPediatrics's stock price is $20.
OrthoPediatrics has current market cap of $494M, and EV of $509M.
See OrthoPediatrics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $509M | $494M | XXX | XXX | XXX | XXX | $-1.11 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, OrthoPediatrics has market cap of $494M and EV of $509M.
OrthoPediatrics's trades at 2.5x EV/Revenue multiple, and -48.7x EV/EBITDA.
Equity research analysts estimate OrthoPediatrics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OrthoPediatrics has a P/E ratio of -14.1x.
See valuation multiples for OrthoPediatrics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $494M | XXX | $494M | XXX | XXX | XXX |
| EV (current) | $509M | XXX | $509M | XXX | XXX | XXX |
| EV/Revenue | 2.3x | XXX | 2.5x | XXX | XXX | XXX |
| EV/EBITDA | 44.2x | XXX | -48.7x | XXX | XXX | XXX |
| EV/EBIT | -15.7x | XXX | -17.2x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -14.1x | XXX | -13.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -12.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOrthoPediatrics's last 12 month revenue growth is 17%
OrthoPediatrics's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.3M for the same period.
OrthoPediatrics's rule of 40 is 11% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OrthoPediatrics's rule of X is 48% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for OrthoPediatrics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 17% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Margin | 5% | XXX | -5% | XXX | XXX | XXX |
| EBITDA Growth | 76% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 11% | XXX | 12% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.4M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 87% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OrthoPediatrics acquired XXX companies to date.
Last acquisition by OrthoPediatrics was XXXXXXXX, XXXXX XXXXX XXXXXX . OrthoPediatrics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was OrthoPediatrics founded? | OrthoPediatrics was founded in 2007. |
| Where is OrthoPediatrics headquartered? | OrthoPediatrics is headquartered in United States of America. |
| How many employees does OrthoPediatrics have? | As of today, OrthoPediatrics has 562 employees. |
| Who is the CEO of OrthoPediatrics? | OrthoPediatrics's CEO is Mr. David R. Bailey. |
| Is OrthoPediatrics publicy listed? | Yes, OrthoPediatrics is a public company listed on NAS. |
| What is the stock symbol of OrthoPediatrics? | OrthoPediatrics trades under KIDS ticker. |
| When did OrthoPediatrics go public? | OrthoPediatrics went public in 2017. |
| Who are competitors of OrthoPediatrics? | Similar companies to OrthoPediatrics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of OrthoPediatrics? | OrthoPediatrics's current market cap is $494M |
| What is the current revenue of OrthoPediatrics? | OrthoPediatrics's last 12 months revenue is $219M. |
| What is the current revenue growth of OrthoPediatrics? | OrthoPediatrics revenue growth (NTM/LTM) is 17%. |
| What is the current EV/Revenue multiple of OrthoPediatrics? | Current revenue multiple of OrthoPediatrics is 2.3x. |
| Is OrthoPediatrics profitable? | Yes, OrthoPediatrics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of OrthoPediatrics? | OrthoPediatrics's last 12 months EBITDA is $11.5M. |
| What is OrthoPediatrics's EBITDA margin? | OrthoPediatrics's last 12 months EBITDA margin is 5%. |
| What is the current EV/EBITDA multiple of OrthoPediatrics? | Current EBITDA multiple of OrthoPediatrics is 44.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
